/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | CMPXCompass Therapeutics |
|---|---|
| Last close | $0.84close 2026-11-09 |
| Change % | +10.29%close 2026-11-09 |
| Market cap | $151Mclose 2026-11-09 |
| P/E | loss, no P/E |
| Revenue | $0⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerIncludingAssessedTax As ofFY ending 2025-12-31 Filing10-K · 0001171843-26-001337 · filed 2026-03-05 Open the filing on EDGAR → |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | -100.0%FY to 2025-12-31 |
| Net income | $-66489000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingDEF 14A · 0001140361-26-017649 · filed 2026-04-29 Open the filing on EDGAR →Open the XBRL payload →CiteCompass Therapeutics, Inc. (CMPX), us-gaap:NetIncomeLoss: -66,489,000 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001140361-26-017649, filed 2026-04-29. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001738021/us-gaap/NetIncomeLoss.json |
| Net margin | zero in the filing |
| EPS (diluted) | $-1.31⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareBasicAndDiluted As ofFY ending 2021-12-31 Filing10-K · 0000950170-22-004156 · filed 2022-03-18 Open the filing on EDGAR →Open the XBRL payload →CiteCompass Therapeutics, Inc. (CMPX), us-gaap:EarningsPerShareBasicAndDiluted: -1.31 USD per share, fiscal year ended 2021-12-31. Form 10-K, accession 0000950170-22-004156, filed 2022-03-18. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001738021/us-gaap/EarningsPerShareBasicAndDiluted.json |
| Piotroski F-ScoreUNVALIDATED | not scored |
| Altman Z-ScoreUNVALIDATED | not scored |
| Beneish M-ScoreUNVALIDATED | not scored |
| Next earnings | 02-27 → 03-09 |